In a subgroup of EGFR T790M negative but G724S mutated and osimertinib-resistant patients, Fassunke et al. demonstrated in vitro that afatinib reduces tumour growth of G724S driven cells [37]. The gene discussed is EGFR; the disease is neoplasm.